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This chapter represents the core of this study and presents the main findings . The 
aim of this chapter is threefold . First, it offers in-depth explanations of the adverse 
drug reaction (ADR) reporting systems, and it describes relevant tasks and actors 
involved in all six countries under consideration (the United Kingdom, Finland, 
Poland, France, Portugal and Germany) . Second, this chapter presents remaining 
challenges and best practices for each case as perceived by the interview partners . 
Third, it provides first recommendations on how to improve the existing systems 
in order to improve ADR reporting and help ensure public health .
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5.1.1 The System
The United Kingdom has a long-established system of pharmacovigilance dat-
ing back to 1964, when the so-called Yellow Card Scheme was introduced there . 
Pharmacovigilance in the United Kingdom is based on a centralised system with 
the Medicines and Healthcare Products Regulatory Agency (MHRA) at its core .
The MHRA is the national competent authority and main regulatory body 
regarding medicines and pharmacovigilance and is an executive agency of the 
Department of Health, which is responsible for matters of legislation and finance .
Through the Yellow Card Scheme, a centralised reporting system reports on 
ADRs which are collected in the MHRA database . With the establishment of regional 
Yellow Card Centres, an element of decentralisation has been introduced . However, 
these centres do not play a direct role in the collection and processing of informa-
tion; they aim to provide advice and training and to raise awareness (cf . below) .
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There is no separate system for reporting ADRs arising from biologicals; the Yel-
low Card Scheme is used for synthetic and biological products alike . This system 
is shown in Fig . 5 .1 .
Reporting
In the 1960s, only physicians and dentists were allowed to report ADRs . However, 
more actors have been included over time . Since the 1990s, additional healthcare 
professionals (pharmacists, nurses and health visitors) have been allowed to report 
as well . After a pilot project, patient reporting was first introduced in 2005 and 
in revamped format in 2008, respectively . Hence, patient reporting in the United 
Kingdom was introduced before the reform of the EU pharmacovigilance system 
with Directive 2010/84/EU .
The way the system works is that both healthcare professionals and marketing 
authorisation holders submit reports to the national competent authority MHRA . 
Patients can report not only to the MHRA directly, but also to authorisation holders 
and healthcare professionals .
Healthcare professionals are not legally but professionally obligated to report 
ADRs and are particularly encouraged to report all serious suspected reactions to 
established medicines, even if the effects are already well recognised . In addition, 
they should report the reactions to the MHRA via the Yellow Card Scheme online 
form, but they can also report them to the marketing authorisation holder .
Moreover, healthcare professionals must report all suspected adverse reactions 
associated with black triangle products (▼), including non-serious ADRs . In the 
United Kingdom, all biological medicines are defined as black triangle products . 
Thus, even though there is no separate system for reporting ADRs related to bio-
logicals, ADRs do receive special attention .
Marketing authorisation holders are legally obligated to report all suspected ADRs 
they are informed about through reports by healthcare professionals or patients or 
in the context of post-authorisation safety studies . Marketing authorisation holders 
process reports from either patients or healthcare professionals in individual case 
safety reports (ICSRs) and subsequently forward them to the MHRA database . 
Non-compliance by the industry might lead to sanctions .
Since 2005, patients are also allowed to report ADRs electronically via the Yel-
low Card Scheme, or by phone or regular mail to the national competent authority 
MHRA . In 2015, the MHRA even introduced the “Yellow Card App” for smartphones . 
Additionally, patients can report to healthcare professionals or the pharmaceutical 
industry, which must transfer the information to the MHRA database .
Furthermore, the National Health Service (NHS), as an active provider of health-
care, has its own database for medical errors and patient safety incidents, i .e . the 
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National Reporting and Learning System . Th e NHS and the national competent 
authority MHRA collaborate closely in order to ensure patient safety . Hence, when 
the National Research and Learning System identifi es an ADR, the NHS forwards 
the information to the MHRA database .
As indicated by Fig . 5 .2, healthcare professionals and marketing authorisation 
holders submitted roughly the same number of reports, while patient reporting 
remained at fi ve to 10 percent in previous years .
Fig. 5.2 ADR reporting by actors (2005-2014) (provided by the MHRA)
Between 2006 and 2012, there were roughly 25,000 reports per year . However, there 
have been substantial increases and the number of ADR reports reached 40,000 in 
2015 . Th e MHRA credits this to general promotion, integrating electronic reporting 
forms into clinical IT systems and the work of the Yellow Card Centres (MHRA 
2016c Annual Report) . In this respect, a signifi cant increase in the reporting of 
both healthcare professionals and members of the public was noted by the MHRA .
Evaluation and Signal Detection
In contrast to pharmacovigilance systems in the other Member States, there is no 
comprehensive evaluation of reports before the stage of signal detection in the 
United Kingdom .
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Therefore, the MHRA database consists of individual case safety reports (ICSRs) 
from the pharmaceutical industry, incidents from the National Report and Learning 
System, data from clinical trials and all ADR reports submitted via the Yellow Card 
Scheme . Additionally, the United Kingdom decided to include serious ICSRs from 
non-EU countries when ADRs relate to medicinal products authorised to be used 
in the United Kingdom .
As a result, the MHRA has to process extremely high numbers of ADR reports, 
and thus signal detection was automated . The MHRA database analyses the reports 
statistically with the Empirical Bayes Geometric Mean (EBGM) method, which is 
able to identify combinations of drug reactions that have been reported unusually 
frequently, and a “disproportionality score” is assigned to each combination (Foy 
2015; MHRA 2016a) .
The MHRA’s Vigilance Intelligence and Research Group meets twice weekly . In 
the first meeting, all synthetic medicines with alarmingly high disproportionality 
scores are discussed . In the second meeting, all serious reports regarding black 
triangle products (▼), i .e . biologicals, are assessed, again indicating that biological 
medicines receive special attention in the United Kingdom .
If signals are detected in either meeting, both statistical methods and a con-
sultation with the Commission on Human Medicines prioritise further action 
(MHRA 2016a) . This could include deciding to update the product information 
leaflet, changing the dosage, issuing warnings in periodic drug safety updates or 
taking the product off the market .
The MHRA has 15 days to report serious cases to EMA .
5.1.2 Perceived Challenges
It is widely assumed in the literature that underreporting is inherent in spontaneous 
ADR reporting . In the United Kingdom, it is estimated that around 10 percent of 
all ADRs are reported; yet, the precise number is dependent on a variety of factors 
and the seriousness of the ADR (see Cousins et al . 2015) .
Lack of Awareness
Evidence suggests that the general awareness about pharmacovigilance is very high 
among healthcare professionals and recent polls show that around 80 percent of 
general practitioners and pharmacists are able to identify the Yellow Card Scheme 
as the ADR reporting scheme (see Cousins et al . 2015) . However, public awareness 
regarding the Yellow Card Scheme is comparably low . A survey revealed that less 
than 10 percent had heard of the scheme (Fortnum et al . 2012) . This number seems 
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to be fairly constant in recent years (Foy 2015) which is surprising, given that patient 
reporting had already been introduced in the United Kingdom in 2005 . Yet, despite 
the long-established system of pharmacovigilance, a significant percentage of the 
general public seems to be unaware of it .
The interviews corroborate this evidence, pointing to a general patient unaware-
ness regarding pharmacovigilance in general and ADR reporting in particular . 
Although the national competent authority MHRA is already engaged in various 
information campaigns (cf . below), public awareness and the knowledge of ADR 
reporting must be further enhanced . While the majority of people have heard of 
the Yellow Card Scheme through pharmacists, advertising in non-medical facilities 
such as public libraries has been suggested (Fortnum et al . 2012) . One example of a 
more target-oriented approach would be to have healthcare professionals hand out 
information brochures when prescribing or administering drugs .
Recommendation: Awareness Raising – Patients
In order to tackle patient underreporting, European, national and regional 
authorities should invest in awareness-raising campaigns to increase the public 
knowledge about pharmacovigilance and reporting of ADRs . Authorities should 
raise awareness in the short term through various means of communication (e .g . 
websites, social media, leaflets) as well as in the long term through cooperation 
with schools to educate future generations .
Moreover, Member States should offer a wide range of possible communica-
tion channels, including web-based as well as paper-based formats . Both formats 
should be designed to be as user-friendly as possible . For web-based formats, IT 
solutions should be developed to guide patients through the format and to ensure 
the completeness of reports . All formats should be accompanied by accessible 
manuals written in layman’s terms .
In addition to measures for facilitating patient reporting, national and regional 
competent authorities should also establish mechanisms to provide mandatory 
feedback to reporting patients .
However, unawareness is not only a challenge regarding patients, but also health-
care professionals, who often underestimate the importance of pharmacovigilance . 
Moreover, there seems to be a lack of sensitivity among healthcare professionals 
that non-serious and especially recurrent ADRs must be reported for an ongoing 
and expedient evaluation .
5.1 ADR Reporting in the United Kingdom 51
51
 
One respondent even indicated that some healthcare professionals appear to 
refuse engaging in ADR reporting because they consider product safety not the 
responsibility of practitioners but the industry producing the medications .
Recommendation: Awareness Raising – Healthcare Professionals
In order to tackle underreporting by healthcare professionals, national author-
ities and healthcare institutions should invest in awareness-raising campaigns 
to increase professional knowledge about pharmacovigilance and to sensitise 
relevant actors about its particular importance to ensure public health .
This lack of awareness should not come as a surprise, though, when considering 
academic education in this field (Smith and Webley 2013) . In the United Kingdom, 
there is no nationwide curriculum covering pharmacovigilance in relevant studies . 
In undergraduate pharmacy degree programmes, pharmacovigilance is compulsory, 
although the amount of time dedicated to it is rather limited . And while pharmacy 
students discuss pharmacovigilance only sporadically, it is rather neglected for 
medical students . Hence, there are no mandatory classes on either pharmacovigi-
lance or ADR reporting . It is argued that particularly causality assessment should 
be a basic subject in all medical schools (Edwards 2012) .
Moreover, several interview partners indicated that there is not enough post-grad-
uate training to keep up with the changing demands . They also lamented that the 
role of EMA and the impact of EU pharmaceuticals regulation on national phar-
macovigilance is neglected (Smith and Webley 2013) . We can thus assume that 
such neglect does not facilitate general awareness among healthcare professionals 
implementing EU regulation at the national level .
Awareness raising is therefore an issue in the long run in order to internalise the 
fact that all ADRs need to be reported for effective signal detection . Both pharmacy 
and medical academic programmes should include mandatory classes emphasizing 
the relevance of pharmacovigilance and imparting information on the practical 
management of ADR reporting . Additionally, the national competent authority 
and related research institutions should offer respective post-graduate training, 
constantly ensuring that practitioners understand the subject’s significance and 
thus notify relevant actors about changing circumstances .
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Recommendation: University and Post-University Training
In order to improve both the quantity and quality of ADR reports, university 
classes about the importance of pharmacovigilance and the need for constant 
ADR reporting should be mandatory for every medical and pharmacy student .
In addition, European, national or regional authorities should organise 
advanced post-graduate training on a regular basis to ensure that healthcare 
professionals acquire the necessary skills to cope with the complex task of ADR 
reporting .
Complexity of ADR Reporting
For biological medicines, the problems are even more severe . Even though United 
Kingdom law prescribes that batch numbers ought to be displayed on each pack-
age, the actual reporting of the number remains rather challenging . Healthcare 
professionals usually struggle with their daily routines in hospitals and do not have 
the time they would need to find and report the respective batch numbers . For pa-
tients, reporting the batch number is generally impossible because biologicals are 
generally administered directly in hospital settings, and therefore patients rarely 
see the respective packaging .
Recommendation: Facilitate Reporting Processes
Healthcare institutions, in line with the general health policies of their Member 
State, should facilitate reporting of ADRs through streamlined internal processes .
Lack of Interconnectivity
Several respondents addressed another concerning challenge, namely the use of 
two different electronic systems, i .e . one for managing patient data and one for 
reporting ADRs . This lack of connectivity between different IT systems renders the 
process of ADR reporting cumbersome and time-consuming and thereby severely 
impedes comprehensive reporting by physicians .
Note that the national competent authority MHRA already integrated the Yellow 
Card Scheme into two hospital systems (cf . below) . This has two major advantages . 
First, it simplifies the reporting process because the system is able to complement 
large amounts of data automatically . Second, the system reminds healthcare pro-
fessionals to report ADRs and makes non-reporting a more conscious decision . 
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Therefore, the integration of the Yellow Card Scheme into all hospital and general 
practitioner software programmes should be pursued further .
Recommendation: Harmonisation of IT Systems
In order to cope with information overload and to facilitate the process of 
submitting ADR reports, national and regional competent authorities should 
improve the interconnectivity of different IT systems, as for instance those of 
general practitioners, hospitals, pharmacies and the national competent author-
ity’s ADR reporting system .
5.1.3 Perceived Best Practices
In the United Kingdom’s pharmacovigilance system, three best practices have 
been identified: active use of social media for awareness raising, interconnectivity 
regarding the Yellow Card Scheme and strong cooperation with other institutions .
Awareness Raising
The MHRA established five regional Yellow Card Centres to further promote the 
Yellow Card Scheme . These centres aim to raise awareness regarding ADR reporting 
and to improve communication between healthcare professionals and patients . In 
order to reach out to patients, the MHRA publishes an electronic newsletter called 
Drug Safety Update for interested patients .
The most important measures to date are as follows:
•	 In March 2013, the Yellow Card Centre of Wales launched the so-called “Yellow 
Card Hospital Champion Scheme” in order to increase awareness and provide 
further incentives for healthcare professionals to report (cf . Box 5 .1) .
•	 In 2014, a new Yellow Card website was launched as a single point of access to the 
reporting scheme, yielding an increase in the number of reports (MHRA 2016) .
•	 In 2015, the 50th anniversary of the Yellow Card Scheme was celebrated with 
special events being held . The MHRA expects that these activities will bear fruit 
in the future due to systematic and cultural change regarding ADR reporting 
(MHRA 2016) .
•	 In 2015, the MHRA launched the Yellow Card App (cf . Box 5 .2) in order to 
offer a platform for information and further simplify patient reporting . Users 
of the smartphone app are able to create individual watch lists to receive official 
information and alerts about medicinal products that are relevant for them .
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Furthermore, the MHRA is considerably engaged in awareness raising via social 
media, e .g . Facebook and Twitter . The hashtag #ThinkPatientSafety, for instance, is 
used to spread news, concerns or information via Twitter . Additionally, the MHRA 
not only uses social media to spread information, but also uses it as a source for 
signal analysis . By searching for specific keywords, statistical MHRA programmes 
are able to identify posts resembling ADR reports .
Although some respondents indicated a lack of sufficient pharmacovigilance 
training for practitioners, the MHRA is not inactive in this respect . For instance, 
it offers extensive guidance on pharmacovigilance and ADR reporting on its web-
site, including free e-learning modules and particular courses for pharmacists and 
nurses to improve their pharmacovigilance skills . The MHRA also publishes general 
information about medical safety issues for all healthcare professionals as well as 
specific information for different specialist groups, if necessary .
Box 5.1 Best Practice: The Yellow Card App
The MHRA’s Yellow Card App was introduced in 2015 as a supplement to the ex-
isting one-stop website and allows patients and healthcare professionals to directly 
report ADRs to the Yellow Card Scheme . The app was created in collaboration 
with the Innovative Medicines Initiative WEB-RADR project and is free to use 
for everyone who has iOS and Android . Besides ADR reporting, users can select 
specific medicines or vaccines to track and receive related news and alerts . More 
precisely, the app enables users to (1) create a watch list of medications in order 
to receive official news and alerts, (2) view numbers of Yellow Cards received 
by MHRA for medicines of interest and (3) receive immediate responses that a 
Yellow Card has been accepted (MHRA, iTunes store) .
Interconnectivity
To begin with, most respondents are very satisfied with the MHRA’s Yellow Card 
Scheme . It enables all actors to report ADRs and facilitates the central collection of 
reports, and the MHRA has already integrated the electronic Yellow Card Scheme 
into two out of five general practitioner software programmes . This profoundly 
simplifies the ADR reporting process, because physicians and pharmacists do not 
have to enter the relevant information twice . Additionally, this step is likely to 
further increase the number of ADR reports submitted by practitioners . Each time 
healthcare professionals intend to enter the termination of a certain medicine into 
the system, there will be a direct request about whether an adverse event ought to 
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be reported . Thus, the awareness about the need to report ADRs is increased and 
the decision not to report becomes much more conscious .
Compared with ADR reporting in other European countries, our respondents 
pointed out that the United Kingdom does not have problems concerning data 
duplication . The MHRA has a special duplication detection programme which is 
able to identify reports that were submitted twice .
Box 5.2 Best Practice: Yellow Card Hospital Champion Scheme Wales
In 2011-2012, the number of Yellow Cards submitted in Wales to the MHRA 
(Medicines and Healthcare Products Regulatory Agency) fell by 26 percent, i .e . 
the lowest annual number from Wales in the past 10 years . Reports submitted by 
hospital pharmacists – before the leading group of reporters – fell by 37 percent 
as compared with the previous year . Similarly, reports from hospital physicians 
fell by 24 percent over the same period .
As a reaction, the Yellow Card Centre Wales (YCC Wales) submitted a proposal 
to the All Wales Chief Pharmacist Committee recommending the introduction 
of a Yellow Card Hospital Champion Scheme as an attempt to improve declining 
reporting rates amongst hospital-based reporters .
All health boards in Wales were asked to nominate a pharmacist or pharmacy 
technician as their “Yellow Card Champion” . All 13 champions received training 
on the Yellow Card Scheme’s background, ADRs and their classification, how 
to complete a Yellow Card, and their new role . They also attended a workshop 
on how to overcome barriers to completing a Yellow Card . In addition, during 
a 12-month period, YCC Wales sent them regular e-mails outlining the latest 
pharmacovigilance news . Altogether, 438 additional healthcare professionals 
received training on the Yellow Card Scheme at 38 sessions .
In 2013-2014, the Wales region collected 1,177 reports of suspected ADRs, 
an increase of 81 percent from 2012-2013 . More precisely, reports from hospital 
pharmacists rose by 189 percent, which represents the highest number of reports 
ever submitted since they have been able to report via the Yellow Card Scheme . 
Hence, the Yellow Card Hospital Champion Scheme has been extraordinarily 
efficient and enabled the YCC Wales to reach a wide audience across all health 
boards in Wales .
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Cooperation
ADR reporting in the United Kingdom is based on the collaboration of all pharma-
covigilance actors, including regulatory authorities and public and private organ-
isations, including patients’ organisations . The collaborative approach is expected 
to facilitate awareness and learning, and it has been suggested that it could serve 
as a template for other countries (Cousins et al . 2015) .
Moreover, the United Kingdom is among the six Member States leading the main 
work packages of the SCOPE implementation project, particularly leading the topics 
in the work packages on ADR collection, signal management, quality management 
systems and risk communications (MHRA 2016) . Taking steps in this direction – 
having both healthcare professionals and patients in mind – seems vital in order 
to address challenges relating to the underreporting of ADRs (Edwards 2012) .
The steps taken in the United Kingdom are specifically geared towards med-
ication errors, which are included in ADR reporting since the reform of the EU 
pharmacovigilance system . In this respect, large healthcare providers are now 
required to have medical safety officers (MSOs) and medical device safety officers 
(MDSOs) . These MSOs or MDSOs are obligated to constantly improve the med-
ication error-reporting system in their respective organisations and to act as the 
main contact for NHS England and the MHRA .
These MSOs and MDSOs are automatically members of the newly founded Na-
tional Medication Safety Network which was set up by MHRA and NHS England; 
this network is a forum for discussing potential and recognised safety issues and 
identifying trends and actions to enhance the safe use of medicines .
Furthermore, the MHRA organises several projects in collaboration with the 
NHS England in order to improve patient safety . Among others, they jointly publish 
“Patient Safety Alerts” to inform the public, healthcare professionals and healthcare 
providers about current safety issues . Recently, the MHRA has also emphasized the 
reporting of ADRs observed in children and young people (MHRA 2016) .
The Commission on Human Medicine is an advisory non-departmental public 
body which works independently and is only accountable to the Department of 
Health . One of the Commission’s sub-committees is the Expert Advisory Group 
for Pharmacovigilance, whose task, inter alia, is to issue recommendations and 
advice on medicinal products to the MHRA .
5.2  ADR Reporting in Finland 57
57
5.2  ADR Reporting in Finland
5.2  ADR Reporting in Finland
5.2.1 The System
The Finnish pharmacovigilance system, which was established in 1982, is headed 
by the Ministry of Social Affairs and Welfare . The Ministry sets the legal guide-
lines but is not actively involved in the system of reporting adverse drug reactions 
(ADRs) . The key actor in the Finnish ADR reporting system is the Finnish Medicines 
Agency (Lääkealan Turvallisuus – Ja Kehittämiskeskus, or Fimea) and it collects and 
evaluates the ADR reports it receives from healthcare professionals, patients, the 
pharmaceutical industry and the National Institute for Health and Welfare (Ter-
veyden Ja Hyvinvoinnin Laitos, or THL) and forwards them to the European level .
As indicated in Fig . 5 .3, the Finnish ADR reporting system differentiates be-
tween synthetic medicines and vaccines; a detailed account of this framework is 
also described below .
Reporting
The Finnish Medicines Agency emphasizes in its guidelines that any ADR ought 
to be reported to the national competent authority . However, Fimea also explicitly 
urges reporting serious and unexpected reactions (Fimea Administrative Guide-
line 2/2013) . Each ADR report submitted by healthcare professionals, patients or 
marketing authorisation holders should include the following information:
•	 Description of the ADR
•	 The suspected drug or medication involved
•	 Drug user data
•	 The course of the event
•	 Information about the person reporting the adverse reaction
•	 The product trade name and the batch number of biological products
Hence, reporting both the trade name and batch number for biologicals is explicitly 
required by the Finnish authorities .
Reporting by healthcare professionals . In Finland, “persons authorised to 
prescribe or supply drugs are advised to report to Fimea any adverse reaction they 
find or suspect in association with the use of drugs” (Fimea Guideline 2/2010, 
emphasis added) . Thus, healthcare professionals are not legally required to report 
ADRs related to synthetic products, although they are legally obligated to report 
ADRs resulting from vaccines .
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ADRs of synthetic products should be reported to Fimea . Physicians and pharmacists 
can report via regular mail or download an online form on Fimea’s homepage and 
then submit the completed form there . In order to report electronically, however, 
healthcare professionals need access to FIMnet; physicians and pharmacists re-
ceive their FIMnet user ID through membership in their respective professional 
associations .
Since 2012, nurses are also allowed to report . Yet, unlike physicians and phar-
macists, they do not have access to FIMnet . Instead, they must print out an online 
form and then submit it via regular mail .
As already described above, ADRs caused by vaccines are treated differently . 
According to the Finnish Communicable Diseases Act (583/1986, 12b), “Healthcare 
professionals must notify all identified or suspected adverse effects of a vaccine that 
have come to their knowledge” (emphasis added) . Here, instead of being advised 
to contact Fimea, healthcare professionals are required to inform the National In-
stitute for Health and Welfare and the institute subsequently sends the respective 
data to Fimea .
Besides reporting to the national competent authority, all healthcare profession-
als, i .e . physicians, pharmacists and nurses, are allowed to inform the respective 
marketing authorisation holder about ADRs . The marketing authorisation holders 
are then legally obligated to forward the reports to Fimea . In the case of non-compli-
ance, marketing authorisation holders risk the launch of infringement procedures 
or the imposition of sanctions . Thus, while healthcare professionals are only legally 
obligated to report ADRs related to vaccines, the pharmaceutical industry is under 
the obligation to report all adverse events to Fimea .
Patient reporting . Since the transposition of Directive 2010/84/EU in 2012, 
patients are also allowed to report ADRs . Similar to nurses, they cannot report 
electronically but need to contact Fimea via regular mail . In addition, patients 
can consult with their treating physician, pharmacist or the respective marketing 
authorisation holder in order to notify them about suspected ADRs . In fact, in 
their “Guidelines on Adverse Drug Reporting”, Fimea specifies that it prefers that 
patients get in touch with healthcare professionals before sending reports directly 
to the national competent authority, arguing that reporting cannot be considered 
a substitute for consulting an expert (Fimea Guideline 2/2010) .
Fig . 5 .4 indicates that in 2015 Fimea received most reports by physicians, i .e . 
1,230 . Physicians especially report reactions to new medicines and those that are 
under special surveillance (e .g . black triangle products (▼)) . In comparison, nurses 
filed 700 reports, which is an impressive number when taking into account that 
they must always jump through the bureaucratic hoops of printing the forms and 
sending them by regular mail . Pharmacists and patients submitted 270 and 400 
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reports, respectively . Thus, in 2015 a total number of 2,600 reports were submitted 
to Fimea (excluding reports by marketing authorisation holders) .
Evaluation and Signal Detection
All reports received by Fimea are entered into the national Adverse Reaction Reg-
ister . The data is coded by specialists and then medically evaluated by healthcare 
professionals and a database . Finally, after evaluation, Fimea forwards the details of 
all ADR reports via regular mail to the respective marketing authorisation holders, 
EMA and the WHO .
Fig. 5.4 ADR reporting by actors in 2015 (provided by Fimea)
5.2.2  Perceived Challenges
Several challenges have been identified by our interviewees, especially regarding 
Fimea’s decision-making power, the actors who are able to report and the connection 
between different healthcare IT systems . 
First, some respondents mentioned that they consider Fimea’s dominance in the 
Finnish pharmacovigilance system problematic . Even though the agency is officially 
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Thus, the result is that only very few people are responsible for making all decisions 
regarding pharmacovigilance and ADR reporting without elaborate supervision .
Lack of Awareness
Generally, our respondents were rather satisfied with the quantity of reports sub-
mitted to Fimea . Some of them, however, indicated that healthcare professionals 
are too focused on reporting serious and new ADRs . Recurrent and non-serious 
ADRs, they claim, are largely neglected and usually unrecorded .
Recommendation: Awareness Raising – Healthcare Professionals
In order to tackle underreporting by healthcare providers, national authorities 
and healthcare institutions should invest in awareness-raising campaigns to 
increase professional knowledge about pharmacovigilance and sensitise relevant 
actors about its importance to ensure public health .
Additionally, and considering Fimea’s particular emphasis on the reporting 
of serious ADRs, reducing this emphasis from the guidelines on ADR reporting 
should be considered . Instead, more prominence should be given to reporting 
all ADRs, including recurrent and non-serious reactions .
Furthermore, our respondents were divided on the particular importance Fimea 
assigns to physicians and pharmacists, namely the only actors in the Finnish ADR 
system who are able to report electronically . Both patients and nurses have to resort 
to regular mail in order to report ADRs . This was perceived as rather unconstruc-
tive by several interviewees because nurses are particularly well trained regarding 
medication and identifying potential ADRs . Thus, prima facie there is no reasonable 
explanation why nurses are excluded from reporting electronically . Additionally, 
physicians are usually rather overworked which might render them unwilling to 
engage in ADR reporting . An additional group of reporters would presumably 
facilitate the process for all actors engaged .
Supposedly, this issue can be traced back to a more cultural explanation, i .e . a 
top-down relationship between physicians and nurses which has been customary 
in Finland for generations . In the Finnish healthcare system, physicians are still 
perceived as the most relevant actors and this status considerably impedes coop-
eration with other healthcare professionals . Thus, facilitating ADR reporting for 
nurses without medical confirmation from physicians would contradict the Finnish 
top-down relationship and impair the perceived “dominant” status of physicians .
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Recommendation: Facilitate Reporting by Nurses
The prestige and perceived infallibility of physicians hinders the development 
of the Finnish pharmacovigilance system . Thus, cultural changes are necessary 
to adjust the level of competence and strengthen the appreciation of nurses to 
improve the process of reporting . The working relationship should be considered 
as cooperative rather than competitive . Nurses should therefore be enabled to 
report electronically, as they are sufficiently educated and would significantly 
reduce the duties and workload of physicians .
Yet not only nurses are impeded from reporting, but also patients are impeded; they 
have to go through the bureaucratic hurdles of searching, printing and mailing a 
reporting form to Fimea instead of using an electronic form . Accordingly, Finnish 
patients need to be very determined if they want to report an ADR to the national 
competent authority .
Despite this, most of our Finnish interview partners strongly support this 
method . They contend that reports submitted by physicians and pharmacists are 
of better quality regarding both completeness and content, while the majority of 
consumer reports include non‐serious or already-listed events which these partners 
consider irrelevant from a signal detection point of view . Hence, impeding patient 
reports has been a conscious decision and is not perceived as a challenge by the 
relevant actors in Finland .
However, what is considered problematic is that patients are not informed about 
the possibility to report at all . Even if Fimea prefers not to be directly contacted 
by patients, the public ought to be informed about the possibility to report via 
consulting physicians and pharmacists . 
Recommendation: Awareness Raising – Patients
In order to tackle underreporting by patients, Fimea, the national competent 
authority, should invest in awareness-raising campaigns to increase the public 
knowledge about pharmacovigilance and reporting of adverse drug reactions .
Authorities should raise awareness in the short term through various means 
of communication (e .g . websites, social media, leaflets) as well as in the long term 
through cooperation with schools to educate future generations .
Moreover, Member States should offer a wide range of possible communication 
channels, including web-based and paper-based formats . Both types of formats
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should be designed to be as user-friendly as possible . For web-based formats, IT 
solutions should be developed to guide patients through the format and to ensure 
the completeness of reports . All formats should be accompanied by accessible 
manuals written in layman’s terms .
Lack of Interconnectivity
ADR reporting for healthcare professionals has been identified as very time-consum-
ing, particularly because there is no IT connection between Fimea’s ADR reporting 
system and the various systems recording patient data . Therefore, our respondents 
regard more IT connectivity between different healthcare systems as a necessary 
step to facilitate ADR reporting . Thus, although most healthcare professionals are 
aware of the importance of reporting, they are impeded from doing so by the rather 
cumbersome reporting system .
However, it should be noted that connecting reporting systems with systems 
storing patient data is currently rather challenging in Finland . The responsibility 
to organise healthcare services is in the hands of 300 municipalities . Because each 
municipality individually decides which patient record system to use, there are 
numerous systems for recording patient data which considerably exacerbates their 
connection and the connection to Fimea’s ADR reporting system .
In the years to come, the Finnish authorities plan to implement a significant 
healthcare reform aiming to transfer responsibilities from the municipal level to 
the regional level . Our respondents expect that afterwards the quality of patient 
record systems is likely to increase and render the connection to ADR reporting 
systems easier .
Recommendation: Harmonisation of IT Systems
In order to cope with information overload and to facilitate the process of submit-
ting ADR reports, national and regional competent authorities should improve 
interconnectivity of IT systems, including those of general practitioners, hospi-
tals, pharmacies and the national competent authority’s ADR reporting system .
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5.2.3 Perceived Best Practices
Awareness Raising
The importance of reporting ADRs is mainly accepted by physicians and pharmacists 
in Finland, even though it is not always easy for them to integrate ADR reporting 
into their daily working routine .
This can be mainly attributed to a very elaborate education system for healthcare 
professionals regarding pharmacovigilance . Pharmacovigilance and ADR report-
ing are part of the mandatory curriculum of both physicians and pharmacists . 
Moreover, pharmacists who are in contact with patients are required to have more 
advanced university degrees . Less-educated people are not allowed to work at the 
counter or to have direct contact with patients and are thus not allowed to report .
Additionally, Fimea offers voluntary advanced training for physicians, nurses 
and medical students, for example at the HUS hospital in Helsinki . During those 
training sessions, current trends, ADR reports and signals are thoroughly discussed, 
leading to high-quality reports .
Reporting of Batch Numbers
ADR reports related to vaccines need to contain not only the brand name, but also 
the product’s batch number . Interestingly, there are barely any problems concern-
ing missing information . As Table 5 .1 reveals, most vaccines that have been in the 
register in 2015 have been identified by their batch number .
Tab. 5.1 How vaccines are identified (provided by THL) (in percent)
2012 2013 2014 2015
Vaccines identified 98 .7 99 .1 99 .4 99 .7
…by batch number 93 .9 95 .4 96 .3 97 .2
…by trade name 3 .8 3 .0 2 .9 2 .2
Vaccines not identified 1 .3 0 .9 0 .5 0 .3
Interconnectivity
Finally, another positive example is the electronic connection between the IT 
systems of physicians and pharmacists . This IT connectivity allows physicians to 
ensure that patients pick up the prescribed drugs at the pharmacies . Even though 
this connectivity could be further improved, it is a promising starting point that 
should be considered by other pharmacovigilance systems across the EU .
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5.3 ADR Reporting in Poland
5.3 ADR Reporting in Poland
5.3.1 The System
The Polish health ministry, although responsible for the health system’s financing 
and its resources, only fulfils a supervisory role in the ADR reporting scheme and 
is not involved in its daily routines .
The Office for Registration of Medicinal Products, Medical Devices and Biocidal 
Products (Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i 
Produktów Biobójczych, or URPL) is the Polish national competent authority for 
the reception and evaluation of all submitted ADR reports . Moreover, the URPL is 
also responsible for forwarding the relevant reports to European and international 
databases . It is affiliated with the national health ministry but acts largely inde-
pendently from it . The URPL is also responsible for educating and training healthcare 
professionals as well as supervising the pharmaceutical industry . In addition, the 
URPL informs health professionals about new developments in pharmacovigilance 
and issues warnings . Because it is technically and professionally competent, it is 
able to influence political discussions on pharmacovigilance and initiates reforms 
in close cooperation with the health ministry .
Fig . 5 .5 illustrates ADR reporting in Poland .
Reporting
Reporting by healthcare professionals . Healthcare professionals, including not only 
physicians, pharmacists and nurses, but also dentists, nurses, midwives, laboratory 
diagnosticians, paramedics and pharmaceutical technicians, are legally obligated 
to report any ADRs; however, there are no anticipated penalties for not doing so . 
Healthcare professionals must complete reports and submit them either to the 
national competent authority URPL or to the marketing authorisation holders in 
question . Moreover, they need to act as contact people for further questions and 
must provide additional information if required . Reports can be submitted by 
e-mail, fax, through regular mail or online .
Reporting by marketing authorisation holders . The pharmaceutical industry, 
which includes the marketing authorisation holders as well as the medicinal product 
manufacturers, is also legally obligated to submit reports on ADRs to the URPL . 
However, in contrast to healthcare professionals, actors in the pharmaceutical indus-
try face non-reporting penalties ranging from paying severe fines to imprisonment .
Patient reporting . The patients, in contrast to the two former actors in the system, 
can submit their reports voluntarily and have three reporting options . They can 
either inform a healthcare professional (mostly the responsible doctor or pharmacist)
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or the marketing authorisation holder in question . Moreover, the patient also has the 
option to report the ADR directly to the URPL office . The report can be submitted 
by e-mail, fax, through regular mail or online .
Evaluation and Signal Detection
The national competent authority URPL receives the ADR reports from patients, 
healthcare professionals and the pharmaceutical industry alike and carries out 
the causality assessment of the reported incidents, evaluating them scientifically 
in order to detect signals . The agency is also able to contact the reporters for ad-
ditional questions or to fill in missing information . Once the report is completed 
and scientifically evaluated, it is forwarded to EudraVigilance and the database of 
the WHO . Moreover, the agency sends feedback to the reporters .
The ADR reporting scheme in general does not differentiate between biological 
and non-biological medicines . However, there is one exception to this rule: Vac-
cines and possible negative side effects stemming from vaccinations are treated in 
a separate system . In Poland, vaccines are administered by healthcare professionals 
mostly working in centres responsible for public health issues . Therefore, the ma-
jority of the vaccines are given by personnel who deal with vaccines on a daily basis 
and are both well-informed about possible negative side effects and well-trained 
to identify possible symptoms . If any ADR is detected, a report is submitted to 
the responsible Regional Sanitary Board, which is obligated to send a copy of the 
report to the URPL . In the case of serious ADRs, the Regional Sanitary Board has 
to inform the State Sanitary Inspectorate which in turn forwards the report to the 
Chief Sanitary Inspectorate (c .f . Fig . 5 .6) .
5.3.2 Perceived Challenges
One of the challenges of the Polish pharmacovigilance system is underreporting, 
although the overall reporting quality is perceived as being good . A number of 
reasons for the non-reporting of ADRs have been identified and are discussed in 
the following paragraphs .
Lack of Awareness
Lack of time and awareness, and the fact that the reporting procedure is perceived 
as being complex and burdensome, lead to non-reporting among healthcare 
professionals . Moreover, a strong hierarchical order within hospitals, which is 
part of the Polish social culture, further impedes efficient reporting . There is the 
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widespread misconception that ADRs only occur in the case of medication errors, 
and thus healthcare professionals are afraid of damaging their own reputations by 
reporting ADRs . Medical supervisors and management boards are also considered 
to be rather restrictive about reporting adverse reactions, trying to avoid reports 
because others’ possible misbehaviour medical errors could be exposed, possibly 
leading to legal consequences such as claims for damages .
Recommendation: Awareness Raising – Healthcare Professionals
In order to tackle underreporting by healthcare providers, national authorities 
and healthcare institutions should invest in awareness-raising campaigns to 
increase professional knowledge about pharmacovigilance and sensitise relevant 
actors about its particular importance to ensure public health .
Additionally, training should include practical and legal counselling in order 
to alleviate the fear of litigation . While respecting national diversity in health-re-
lated and legal terms, it is important to recognise that fault-based systems are a 
significant impediment to ADR reporting . A general and cautious recommen-
dation would be to enable healthcare professionals to report ADRs without fear 
of liability . This could be pursued not only by practical and legal counselling for 
healthcare professionals, but also by legal means through strengthening confi-
dentiality or setting up compensation schemes for patients’ claims .
The Polish pharmacovigilance system faces the insufficient education of professionals 
on the topic, because pharmacovigilance is not taught in a coordinated manner 
at the medical and pharmaceutical faculties at the country’s universities . Instead, 
education and training for students remain dependent on the personal engage-
ment of single professors . A systematic organisation for training is also lacking 
for healthcare professionals . In addition, the options for continuous training and 
professional development programmes are very limited .
Recommendation: University and Post-University Training
In order to improve both the quantity and quality of ADR reports, university 
classes about the importance of pharmacovigilance and the need for constant 
ADR reporting should be mandatory for every medical and pharmacy student .
In addition, the URPL should organise advanced post-graduate training on a
5.3 ADR Reporting in Poland 69
69
regular basis to ensure that healthcare professionals acquire the necessary skills 
to cope with the complex task of ADR reporting .
The lack of a sound academic and professional network of pharmacovigilance in 
Poland is also perceived as a challenge to the system . Although a number of insti-
tutes and organisations are engaged in the national pharmacovigilance system and 
research in this field, there is only a very limited, informal exchange of information 
and study results . Experience and new insights can get lost because of the lack of 
academic and professional interconnections .
Patients are not sufficiently educated on pharmacovigilance and know very 
little about the possibilities to report ADRs . Although first steps have been taken 
to educate the public about pharmacovigilance and adverse events (cf . Box 5 .3), 
many gaps remain . Moreover, better-educated patients can also possibly monitor 
healthcare professionals and motivate them towards more active ADR reporting . 
The patients’ advantage is that the repercussions of the hierarchical hospital system 
and possible professional consequences do not affect them .
Recommendation: Awareness Raising – Patients
In order to tackle underreporting by patients, the URPL should invest in aware-
ness-raising campaigns to increase the public knowledge about pharmacovigilance 
and the reporting of ADRs .
Authorities should raise awareness in the short term through various means 
of communication (e .g . websites, social media, leaflets) as well as in the long term 
through cooperation with schools to educate future generations .
Moreover, Member States should offer a wide range of possible communication 
channels, including web-based and paper-based formats . Both web-based and 
paper-based formats should be designed to be as user-friendly as possible . For 
web-based formats, IT solutions should be developed to guide patients through 
the format and to ensure the completeness of reports . All formats should be 
accompanied by accessible manuals written in layman’s terms .
Incomplete Reports
The Polish pharmacovigilance scheme is relatively inexperienced in tracking and 
using biologicals . Because the Polish pharmaceutical industry is focused on pro-
ducing generic drugs, professionals and also predominantly the national competent 
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authorities are rather inexperienced in monitoring and supervising biological med-
icines . Hence, the ADR reporting scheme does not differentiate between biological 
and non-biological medicines, except for vaccinations . Thus, not only risks, but also 
benefits of biological medicines can be underestimated and warning signs can be 
overlooked due to inexperience in the field . Moreover, these both lead to problems 
in ADR reporting . Due to the relative inexperience with biologicals and a lack of 
training, batch numbers are not coherently reported and traceability is hampered .
Recommendation: Training on Biological Products
European, national or regional authorities should organise advanced post-grad-
uate training on a regular basis to ensure that healthcare professionals acquire 
the necessary skills to cope with the complex task of ADR reporting .
In order to tackle underreporting of batch numbers and thereby facilitate the 
correct and timely traceability of biologicals, healthcare professionals should 
receive additional training to both increase awareness about the particular 
relevance of ADR reporting related to biologicals and to acquire the necessary 
skills to do so .
Budgetary Constraints
The national competent authority URPL has very limited personnel capacities and 
limited financial resources which both restrain its scope of actions; each year, the 
number of submitted reports increases while the workforce remains the same . 
Hence, reports cannot be evaluated as fast as would be desired . In addition, ADR 
reporting by telephone cannot be done because it would take too much time .
Recommendation: Sufficient Financial Means for Relevant Actors
National and regional competent authorities working under the auspices of 
national ministries should be endowed with sufficient financial means to fulfil 
their functions . Likewise, healthcare institutions should be endowed with suffi-
cient means . Sound finances enable healthcare institutions to rely on a stronger
workforce which reduces the workload of individual healthcare professionals 
and increases the possibility of extended the reporting of ADRs .
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5.3.3 Perceived Best Practices
Awareness Raising
The URPL aims at spreading information and raising awareness in the general 
public, not only to educate patients, but also to reach healthcare professionals . 
The agency uses different social media accounts (cf . Box 5 .3), and has produced 
two animated movies (URPL 2016) which explain how to report ADRs and offer 
training for professionals .
Box 5.3 Best Practice: URPL on social media
The Polish URPL is very active on social media with a Twitter and Facebook 
account as well as a YouTube channel . The authority posts news, interesting 
insights and information on pharmacovigilance, among other URPL topics . It 
uses the hashtag #safedrug to promote knowledge about ADR reporting and phar-
macovigilance . Moreover, URPL published two animated movies which explain 
how to report an ADR and adverse events to the authority (URPL 2014, 2015) .
Reporting System for Vaccines
A positive example, especially for the ADR reporting of biological medicines, is 
the reporting scheme for negative effects deriving from vaccines (cf . Fig . 5 .6) . The 
system is different from the general ADR reporting scheme because it follows a 
decentralised approach for reporting vaccine ADRs . Physicians and feldshers are 
legally obligated to report ADRs stemming from vaccines to the Regional Sanitary 
Board . Other healthcare professionals can voluntarily file an ADR report but are 
not obligated to do so .
The Regional Sanitary Board receives the ADR report, adds it to a database that 
stores ADR reports on vaccines for 10 years, and is obligated to forward a copy of 
the report to the national competent authority URPL . With a serious ADR event, 
the regional unit has to inform the State Sanitary Board (Wojewodzki Inspektorat 
Sanitarny, or WIS) within an hour after receiving the report . The WIS in turn in-
forms the Chief Sanitary Inspectorate (Główny Inspektorat Sanitarny, or GIS) . The 
GIS keeps records of all ADRs caused by vaccines and publishes a yearly report .
This system enables a close monitoring of ADRs resulting from vaccinations, and it 
ensures high numbers of reporting because it is well-known and broadly accepted 
among professionals . In addition, batch number reporting functions well because 
the personnel is trained accordingly .
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5.4 ADR Reporting in France
5.4 ADR Reporting in France
5.4.1 The System
Since 1973, pharmacovigilance in France has been organised by a decentralised 
network of 31 regional centres (Centres Régionaux de Pharmacovigilance, or CRPVs) 
and the national competent authority, namely the Agency for Drug Safety and Health 
Products (Agence Nationale de Sécurité de Médicament et des Produits de Santé, or 
ANSM) . While the CRPVs are in charge of data collection and validation, the ANSM 
is responsible for data evaluation and overall decision-making processes . The French 
Ministry for Health and Social Security is responsible for the legal framework, 
finances, and the overall supervision of the French pharmacovigilance system .
The process of adverse drug reaction (ADR) reporting in France is illustrated 
by Fig . 5 .7 and explained in the following sections . Currently, there is no separate 
system for reporting ADRs arising from biologicals, so the system outline below 
refers to the reporting of both synthetic and biological medicines .
Reporting
Reporting by healthcare professionals . Healthcare professionals constitute one of the 
major pillars of the French ADR reporting system . Physicians, dentists, pharmacists 
and midwives are legally obligated to report any ADR they encounter (Loi de l’etat 
2011-2012 du 29 décembre 2011 relative au renforcement de la sécurité sanitaire du 
médicament et des produits de santé); non-compliance can lead to three years of 
imprisonment and a fine of up to €45,000 (ibid ., Article 28) .
According to French legislation, healthcare professionals must file a report to 
the regional CRPV where the patient is based that contains all the necessary in-
formation . Reports can be submitted via regular mail, e-mail, via an online form 
or by fax . During the evaluation procedure in the regional centres, healthcare 
professionals act as contact points and must be open to follow-up questions from 
the regional CRPV’s experts .
Reporting by the pharmaceutical industry . In addition, the pharmaceutical 
industry has the legal obligation to file a report on every ADR it is informed about 
and any failure to comply can result in a fine of up to €150,000 and two years’ im-
prisonment (Code de la santé publique, Article L . 5421-5) . The respective marketing 
authorisation holders must send the report directly to the national competent 
authority ANSM, again by regular mail, e-mail or via an online form .
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Patient reporting . Finally, since June 2011, patients have also been empowered to 
report ADRs, although they can report on a voluntary basis . If a patient suspects an 
ADR, he or she has different options for reporting . First, the patient can choose to 
inform the regional pharmacovigilance centres or the ANSM by mail, fax and often 
via an online form . Interestingly, a study by Health Action International (Santos 
n .d .: 13) found that “in France, about half of the regional pharmacovigilance cen-
tres did not appear to have their own website to report ADRs” and only very few 
were found to allow direct online reporting . Further, a patient has the possibility 
to directly contact the marketing authorisation holder for the medicinal product 
in question . Third, the patient can consult a healthcare professional for advice and 
assistance in reporting .
Some regular centres provide feedback to reporters . As Health Action Interna-
tional (Santos n .d .: 8) summarised: “Toulouse, for example, sends a letter to patients 
who report an ADR . It includes a summary of the report and its assessment and the 
extent to which the report has been transferred to the national database . Relevant 
scientific publications can also be attached” .
Evaluation and Signal Detection
All reports submitted by healthcare professionals and patients are collected by the 
31 regional pharmacovigilance centres which are located in university hospitals 
all over the country . The regional CRPVs’ pharmacovigilance units scientifically 
evaluate the reports and conduct the causality assessments . After verification by 
CRPV experts, the reports are collected in the French pharmacovigilance database 
(FPD) which is hosted by the ANSM; the reports submitted by marketing authori-
sation holders are directly sent to the FPD .
There are monthly meetings between the heads of the regional centres and the 
ANSM’s Technical Committee (Caron et al . 2014) . This committee is responsible for 
collecting and evaluating further information about ADRs, assessing the evaluated 
reports for trends in order to detect larger signals and, subsequently, forwarding 
these to the ANSM’s general director . If deemed necessary, the committee forwards 
their findings to the EMA and the international database of the WHO .
In 2014, the ANSM received 46,497 ADR reports (initial and follow-up) from 
the regional centres, 1,983 of which were submitted by patients (ANSM Annual 
Report 2015) .
76 5   Practical Implementation in Six Member States﻿
5.4.2 Perceived Challenges
The French pharmacovigilance system is suffering from the aftermath of the so-called 
Mediator scandal which cost more than 2,000 deaths as a consequence of serious 
delays in ADR reporting and an inadequate reaction from the national competent 
authority (cf . Box 5 .4) . Many of our respondents emphasised that this scandal has 
still not been entirely processed by the French pharmacovigilance system and the 
actors involved . Instead, the respondents pointed out that many systematic difficulties 
remain, considerably impeding efficient and independent pharmacovigilance . For 
instance, it is not explicitly prohibited to work for the pharmaceutical industry and 
to be a member of the national competent authority at the same time . Consequently, 
conflicts of interest of ANSM committee members regarding the monitoring me-
dicinal products are still present . And even though conflicts of interests formally 
need to be declared, there is no penalty for not doing so .
All of our respondents indicated that the French pharmacovigilance system 
currently faces numerous challenges . Again, underreporting is considered one of 
the major weaknesses . Several reasons for this have been identified by our inter-
viewees and are discussed in the following sections .
Lack of Awareness
First, the relevant actors in the French pharmacovigilance system are often unaware 
either of their obligation to report ADRs or the importance of reporting ADRs, 
especially those arising from biological medicines . This leads many healthcare 
professionals to completely neglect this issue in the course of their daily routines .
Recommendation: Awareness Raising – Healthcare Professionals
In order to tackle underreporting by healthcare providers, national authorities 
and healthcare institutions should invest in awareness-raising campaigns to 
increase professional knowledge about pharmacovigilance and sensitise relevant 
actors about its importance to ensure public health .
This training should especially increase understanding about the particular 
relevance of ADR reporting related to biologicals and impart the necessary 
skills to do so .
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Complexity and Lack of Interconnectivity
In addition, several interview partners mentioned that the workload of healthcare 
professionals was already considerable; therefore, healthcare professionals often 
refuse to engage in ADR reporting, perceiving it as a time-consuming and complex 
task which is difficult to integrate into daily routines . Administrative hurdles also 
make it difficult for healthcare professionals to report . First, reports need to be 
submitted via a separate online portal, and thus information needs to be collected 
from different IT systems . Patients must also be informed . In addition, practitioners 
are expected to be available for any follow-up questions from the regional centres . 
In summary, ADR reporting turns into a long process which cannot simply be 
reduced to the mere submission of a report .
Recommendation: Facilitate ADR Reporting Processes
Healthcare institutions, in line with the French general health policies, should 
facilitate ADR reporting through streamlined internal processes .
In order to cope with information overload and to facilitate the process of 
submitting ADR reports, national and regional competent authorities should 
improve the interconnectivity of IT systems, such as those of general practitioners, 
hospitals, pharmacies and the ANSM’s ADR reporting system .
Additionally, all stakeholders at the national level should improve mechanisms 
of cooperation . This not only includes competent authorities, but also industry and 
patients’ associations as well as research and training facilities such as universities .
Box 5.4 The 2009 Mediator scandal in France
From 1976 to 2009, the French manufacturer Laboratoires Servier sold the drug 
benfluorex under the brand name Mediator on the French market . The product 
was originally designed to control the weight of patients suffering from diabetes 
or obesity . However, it was often prescribed off-label to people with no other 
medical indications as an appetite suppressant for facilitating weight loss . In 
the early 2000s, the first studies found that the medication causes cardiac valve 
damage and pulmonary hypertension . Despite repeated warning signs and 
studies pointing at the causality between taking the drug and cardiac illnesses, 
however, neither the French authorities nor Laboratoires Servier reacted . Only in 
2009 did the national agency AFSSAPS (now the national competent authority 
ANSM) finally ban the drug and investigations were started by an independent
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commission . The final report argues that both the company as well as the coun-
try’s regulatory system are responsible for this medical scandal, which caused an 
estimated 2,000 deaths and led to many more patients being hospitalised with 
cardiac problems (Mullard 2011; Casassus 2016) .
Fear of Litigation
ADRs can occur despite medications being correctly prescribed and correctly 
administered . However, our respondents indicated that French healthcare profes-
sionals still often consciously avoid reporting ADRs due to a fear of litigation and 
loss of reputation . Reporting an ADR is still often considered akin to confessing 
to a medical error .
Recommendation: Legal Counselling
The previously suggested pharmacovigilance training should include both 
practical and legal counselling in order to alleviate the fear of litigation . While 
respecting national diversity in health-related and legal terms, it is important to 
recognise that fault-based systems are an important impediment to the report-
ing of ADRs . A general and cautious recommendation is to enable healthcare 
professionals to report ADRs without fear of liability . This could be pursued not 
only by practical and legal counselling for healthcare professionals, but also by 
legal means through strengthening confidentiality or setting up compensation 
schemes for patients’ claims .
Incomplete Reports
Another closely related problem identified by our interviewees is the weak quality 
of submitted reports . Frequently, brand names or relevant patient information is 
either inaccurate or completely omitted, and reported batch numbers appear to be 
the exception, especially with biological medicines . The varying quality of ADR 
reports thus exacerbates sound causality assessments and often renders them im-
possible . This emphasizes the need for a separate system regarding the reporting of 
biological medicines in order to guarantee sound monitoring and an appropriate 
risk-benefit assessment .
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Recommendation: Training on Biological Products
European, national or regional authorities should organise advanced post-grad-
uate training on a regular basis to ensure that healthcare professionals acquire 
the necessary skills to cope with the complex task of reporting ADRs .
In order to tackle underreporting of batch numbers and thereby facilitate the 
correct and timely traceability of biologicals, healthcare professionals should 
receive additional training to both increase awareness about the particular 
relevance of ADR reporting related to biologicals and to acquire the necessary 
skills to do so .
Budgetary Constraints
Finally, public health seems not to be an economic priority . This is visible not only 
from the Mediator scandal, but also in the dependencies faced by the regional cen-
tres that rely on financing from the state budget and political priorities set by the 
Health Ministry . Thus, regional budgets are rather limited and pharmacovigilance 
does not appear to be high on the political agenda .
Recommendation: Sufficient Financial Means for Relevant Agencies
National and regional competent authorities working under the auspices of 
national ministries should be endowed with sufficient financial means to fulfil 
their functions . Likewise, healthcare institutions should be endowed with suffi-
cient means . Sound finances enable healthcare institutions to rely on a stronger 
workforce which reduces the workload of individual healthcare professionals 
and increases the possibility of extended reporting of adverse drug reactions .
5.4.3 Perceived Best Practices
However, besides these challenges and the system’s shortcomings, the French 
pharmacovigilance system also exhibits very positive aspects, as discussed below .
Decentralisation
As emphasized by our respondents, one of the major advantages is the decentralised 
approach to ADR reporting . The close proximity of the 31 regional pharmacovigi-
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lance centres situated in hospitals all over the country allows the experts to be close 
to both healthcare professionals and patients . Moreover, the regional experts are 
able to keep in contact with both medical and pharmacy students . This profoundly 
facilitates communication between the relevant reporting and evaluating actors, and 
the experts remain visible in the healthcare professionals’ daily working routine .
Besides collecting and evaluating the reports as well as acting as contact points 
between reporting actors and the ANSM, the regional centres are also active in research 
and education . They offer training on pharmacovigilance for healthcare profession-
als, provide information and expert advice, and serve as the first contact points for 
patients and practitioners alike . The regional units also provide information on the 
efficacy and safety of the medicinal products to healthcare professionals and patients .
Furthermore, the reports’ assessment and evaluation has been pointed out as 
advantageous by our interviewees . For each individual case, a causality assessment 
is conducted . Each report is scientifically evaluated by the regional units before it 
is forwarded to the ANSM . Thus, low-quality and invalid reports can be largely 
eliminated before they are entered into the FPD, EMA or WHO databases .
As one of our respondents emphasized, leaving the evaluation to pharmacovig-
ilance experts, usually pharmacists or physicians, was a conscious decision by 
the relevant actors . Collecting huge amounts of data and leaving signal detection 
to an algorithm, as for instance in the United Kingdom, was perceived as rather 
unconstructive .
Awareness Raising
In addition, our respondents identified several good examples regarding education . 
First, there are some university professors who are specialised in pharmacovigilance . 
Although they are few, they have a positive influence because they put pharma-
covigilance on the agenda of medical faculties and academia . Pharmacovigilance 
professors enhance the healthcare professionals’ knowledge through academic 
publications, conferences and awareness raising .
Second, a master’s programme on pharmacovigilance (cf . Box 5 .5) with different 
specialisations was established by the University of Bordeaux . This programme aims 
not only at training future professionals in pharmacovigilance and pharmacoepi-
demiology, but also focuses on establishing an international network of academics 
and professionals alike which fosters the exchange of knowledge and expertise .
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Box 5.5 Best Practice: Master’s Degree in Pharmacovigilance and 
Pharmacoepidemiology
This master’s programme is coordinated by the University of Bordeaux and aims at 
training future professionals in pharmacovigilance as well as fields connected with 
this issue . Aside from offering basic courses in pharmacovigilance and epidemi-
ology, the programme provides courses in risk identification, pharmacovigilance 
regulations, public health and risk communication . Moreover, workshops with 
experts from regulatory agencies and the pharmaceutical industry are held in 
order to ensure the subjects’ practical relevance, as the graduates are expected to 
work in industry, regulatory bodies and academia alike . Universities from other 
European countries also participate in this programme to ensure high academic 
expertise and an international exchange of knowledge .
5.5 ADR Reporting in Portugal
5.5 ADR Reporting in Portugal
5.5.1  The System
The Portuguese pharmacovigilance system was introduced in 1992 . The National 
Authority of Medicines and Health Products (Autoridade Nacional do Medicamen-
tos e Produtos de Saúde, I.P ., or INFARMED) is the country’s national competent 
authority . It supervises and coordinates the regional units and maintains the 
national ADR database, and is affiliated with the National Health Ministry which 
is responsible for legislative matters .
The Portuguese pharmacovigilance framework was initially devised as a cen-
tralised system, but in the early 2000s turned into a decentralised system (see 
Duarte et al . 2015; Marques et al . 2015) . Today, it is based on four regional pharma-
covigilance centres that are in line with Portugal’s administrative regions (North, 
Centre, Lisbon, South) . The four regional centres are responsible for collecting, 
processing and evaluating adverse drug reaction (ADR) reports and maintain their 
own databases (Mendes et al . 2014) .
In doing so, the regional centres collaborate with INFARMED . The Risk Man-
agement for Medicines Directorate (Direção de Gestão do Risco de Medicamentos) 
of INFARMED coordinates the national pharmacovigilance database .
There is no separate system for reporting ADRs arising from biological medicines .
The Portuguese ADR reporting system is shown in Fig . 5 .8 .
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Reporting
In recent years, Portugal has developed a robust pharmacovigilance system, with 
several actors being allowed to report ADRs (Marques et al . 2016) . At the time of 
system creation in 1992, only physicians were allowed to submit reports . However, 
pharmacists and nurses were included in 1995 and 1999, respectively . With Directive 
2010/84/EU, patients have become the latest addition; today, ADRs can be reported 
by market authorisation holders, healthcare professionals and patients .
While healthcare professionals and patients submit their reports to the regional 
pharmacovigilance centres, the respective marketing authorisation holders directly 
report to the INFARMED sub-unit that is responsible for medicinal risk management .
Reporting by healthcare professionals . All healthcare professionals are legally 
obligated to report any ADR . Officially, non-compliance is sanctioned . In practice, 
however, sanctions are not enforced . Healthcare professionals, i .e . physicians, dentists, 
pharmacists, nurses and medical-technical assistants, are a vital part of the phar-
macovigilance system . Depending on their postal code, they have to report adverse 
reactions to the respective regional centre and need to be available for follow-up 
questions . A majority of reports is issued by physicians and pharmacists, although 
some reports are submitted by nurses and medical-laboratory assistants . Healthcare 
professionals can submit their reports via online forms, e-mail, fax or regular mail .
Reporting by marketing authorisation holders . Marketing authorisation holders 
are under a legal obligation to report any ADR as well . Yet, while healthcare pro-
fessionals and patients report to the regional units, the pharmaceutical industry 
submits its reports directly to INFARMED .
Patient Reporting . Since 2013, patients are also allowed to report suspected 
ADRs to the regional pharmacovigilance centres . In contrast to professionals and 
the industry, however, their reports are optional . Reports can be submitted by a 
number of options, including by telephone, fax, regular mail, e-mail or the online 
forms provided by the regional centres or INFARMED .
As illustrated by Fig . 5 .9, since 2005, marketing authorisation holders submit 
the majority of reports to INFARMED, followed by physicians and pharmacists . 
Nurses and patients bring up the rear .
The number of reports has been steadily increasing since the introduction of the 
system in 1992 (INFARMED 2010) . In 2013, the year in which patient reporting was 
introduced, the number was around 3,400 (Santos n .d .) and in 2014, the number was 
around 4,600 (Matos et al . 2015) . In 2015, the number was around 5,600 (INFARMED 
2016) . The number of reports submitted by patients, however, is very small, with 
only 175 reports in 2014 (Santos n .d .) . There is also considerable variation in terms 
of reporting by the regional pharmacovigilance centres (Ribeiro-Vaz et al . 2016) .
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Evaluation and Signal Detection
ADR reports submitted by healthcare professionals and patients are collected by 
the four regional pharmacovigilance centres . The centres receive reports by patients 
and healthcare professionals assigned by postal code and evaluate them with a 
team of physicians and pharmacists . Reports submitted by marketing authorisa-
tion holders are directly sent to and assessed by INFARMED’s Directorate of Risk 
Management for Medicines .
During the processing of ADR reports, the centres keep in touch with the re-
porters or directly with the patient, and the necessary information is cross-checked 
regarding the causality assessment and final review of the adverse reactions . The 
causality assessment is usually done by clinicians (Inácio et al . 2015) . Usually, the 
regional centres have 30 days from the report’s submission for a comprehensive 
causality assessment before forwarding the report to INFARMED .
Signal detection includes the identification and management of signals and is 
conducted by the Risk Management for Medicines Directorate of INFARMED . 
To this end, individual case safety reports (ICSRs), literature and other sources 
are considered .
In terms of methodology, INFARMED uses multiple approaches, including 
computerised signal detection methods . However, despite these methods, the 
assessment of ICSRs remains the most relevant information (INFARMED 2010) .
5.5.2 Perceived Challenges
Similar to other countries, underreporting by both healthcare professionals and 
patients was perceived by our interview partners as a significant shortcoming . The 
reasons for underreporting are twofold: lack of awareness and time constraints .
Lack of Awareness
First, it has been lamented that the relevant actors are not sufficiently informed 
that they are able to report . In Portugal, this refers especially to patients . Because 
patients could only submit reports after Directive 2010/84/EU was transposed 
into Portuguese legislation in 2013, they are still not yet sufficiently aware of both 
the possibility to do so and the subject’s importance . Despite the fact that patient 
reporting increased in 2014 and 2015 (cf . Fig . 5 .8), indicating that awareness rais-
ing is in fact taking place, patients should be more thoroughly informed about the 
possibility to report ADRs .
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Recommendation: Awareness Raising – Patients
In order to tackle underreporting by patients, European, national and regional 
authorities should invest in awareness-raising campaigns to increase the public 
knowledge about pharmacovigilance . Even though awareness raising is already 
taking place in Portugal, efforts in this regard should be enhanced .
However, unawareness is not only a challenge regarding patients, but also regarding 
healthcare professionals . Here it is important to note that the Portuguese pharmacovig-
ilance system was initiated in the 1990s as a top-down project, and therefore education 
on this subject is also rather new . Hence, many healthcare professionals are simply 
not informed about their legal obligation to report every single ADR they encounter .
Moreover, even if healthcare professionals know that they are obligated to report, 
many physicians and pharmacists are unaware of the importance of reporting all 
ADRs, and not only new or serious ones . More precisely, while patients are often 
not aware of the fact that they are able to report, healthcare professionals tend to 
report only serious or formerly unknown ADRs . Recurrent and non-serious ADRs 
are largely neglected .
In addition, numerous healthcare professionals do not seem to be aware of the 
need to report batch numbers in order to ensure the accurate and timely traceability 
of biological medicines . 
All this is especially problematic if the hospital management is also not adequately 
educated and hence does not consider ADR reporting sufficiently important . Suf-
ficient ADR reporting also depends on the hospital management boards because 
they can make pharmacovigilance a priority in the working environment and train 
their medical staff accordingly . However, the management is often perceived as 
impeding education on the topic and neglecting the issue’s importance . Although 
it is already impeding ADR reporting if practitioners do not consider it relevant, it 
might be even more dangerous if their superiors label it as insignificant and therefore 
do not offer practitioners the respective time, information and training they need 
to report in a responsible manner . This insufficient sense of importance often leads 
to insufficient prioritisation of the task, which in turn continues to hinder effective 
ADR reporting in Portugal .
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Recommendation: Awareness Raising – Healthcare Professionals
National authorities and healthcare institutions should invest in awareness-rais-
ing campaigns to increase professional knowledge about pharmacovigilance and 
sensitise relevant actors about its particular importance to ensure public health .
In order to improve both the quantity and quality of reports on adverse drug 
reactions (ADRs), university classes about the importance of pharmacovigilance 
and the need for ADR reporting should be mandatory for every medical and 
pharmacy student .
Further, healthcare professionals – including hospital management – should 
receive additional training to both increase awareness about the particular 
relevance of ADR reporting related to biologicals and to acquire the necessary 
skills to ensure the reporting of batch numbers, thereby facilitating the correct 
and timely traceability of biologicals .
Fear of Litigation
Finally, our interview partners mentioned another issue potentially resulting in 
the underreporting of ADRs . Even if healthcare professionals are aware of the im-
portance of reporting and have sufficient time to report, they might be unwilling 
to do so in cases of off-label use . Regardless of the underlying cause of adverse 
effects, off-label use, medication errors or otherwise, the legal repercussions are a 
serious concern for healthcare professionals . Hence, it is vital to emphasize that any 
reporting system should be geared towards the quality of healthcare services and 
thus be separated from legal proceedings (see EMA 2013) . From this perspective, 
healthcare providers must be assured that ADR reporting has no legal repercussions .
Recommendation: Legal Counselling
The suggested training should include practical and legal counselling in order to 
alleviate the fear of litigation . While national diversity in health-related and legal 
terms should be respected, it is important to recognize that fault-based systems 
are a significant impediment to reporting ADRs . A general and cautious recom-
mendation is to enable healthcare professionals to report ADRs without fear of 
liability . This could be pursued not only through practical and legal counselling 
for healthcare professionals, but also by legal means through either strengthening 
confidentiality or setting up compensation schemes for patients’ claims .
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Budgetary Constraints
Another challenge pointed out by our respondents is the lack of time to report . This 
is particularly the case in hospital environments in which physicians and nurses 
are usually rather overworked . According to our interviewees, adding the compre-
hensive reporting of every ADR to the usual workload therefore appears to be too 
challenging . Again, this is a particular obstacle for ADR reporting of biological 
medicines, the majority of which are dispensed in hospitals .
Thus, there is a perceived shortage of financial and especially human resources 
which mainly results from lean budgets following the economic crisis in Southern 
Europe . During the crisis, relevant actors even feared that the pharmacovigilance 
system could be suspended altogether due to the lack of resources and lack of po-
litical priority . The Portuguese pharmacovigilance system is only slowly recovering 
from the deep financial and personnel cuts in the recent years .
Recommendation: Sufficient Financial Means for Relevant Agencies
National and regional competent authorities working under the auspices of 
national ministries should be endowed with sufficient financial means to fulfil 
their functions . Likewise, healthcare institutions should be endowed with suffi-
cient means . Sound finances enable healthcare institutions to rely on a stronger 
workforce which reduces the workload of individual healthcare professionals 
and increases the possibility of extended reporting of adverse drug reactions .
5.5.3 Perceived Best Practices
In Portugal’s pharmacovigilance system, identified best practices are associated 
primarily with the four regional pharmacovigilance centres . These best practices 
concern awareness raising and cooperation .
Awareness Raising
The regional pharmacovigilance centres actively engage in awareness-raising 
campaigns in order to increase the knowledge and perceived importance of phar-
macovigilance in general and ADR reporting in particular . In order to sensitise 
these actors about the importance of ADR reporting, regional centres offer in-
ternships for pharmacy and medical students, provide lectures and training on 
pharmacovigilance, and disseminate further relevant information . The southern 
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unit, for instance, educates selected pharmacists on pharmacovigilance and the 
ADR reporting system .
However, healthcare professionals are not the only target group as many activities 
are geared towards the general public . One respondent, for instance, mentioned 
cooperation with public schools aiming to educate both children and their parents .
Cooperation
The aforementioned decentralisation has proven to be vital to strengthen the cooper-
ation of pharmacovigilance centres with universities (Inácio et al . 2015) . All regional 
centres are located within research institutions allowing for close cooperation with 
the relevant actors in ADR reporting . While the units for Lisbon, South and North 
are located directly within the universities’ medical or pharmacy faculties, the 
pharmacovigilance unit of the centre region is located within the Association for 
Innovation and Biomedical Research on Light and Image, a research technology 
organisation dedicated to the development and clinical research of new products 
for medicinal therapy and diagnostic imaging .
The regional centres seek to increase the available data on ADRs by collaborating 
with healthcare organisations . After the initially low number of ADR reports, the 
northern centre, for instance, established a collaboration protocol with nearby 
hospitals to collect every suspected case of ADR (Ribeiro-Vaz et al . 2016) . This 
approach requires close collaboration at the personal level between the staff of 
the pharmacovigilance centre and hospitals . As another instance, respondents 
identified the collaboration between the southern centre and the rheumatology 
association . Such close collaboration between the pharmacovigilance centres and 
other healthcare providers can lead to more and reliable data which considerably 
facilitates the reports’ evaluation and respective signal detection .
Hence, the work by the four regional pharmacovigilance units and especially 
their strong cooperation with other relevant actors and active engagement in 
awareness-raising activities has been perceived as particularly conducive to the 
Portuguese pharmacovigilance system .
90 5   Practical Implementation in Six Member States﻿
5.6  ADR Reporting in Germany
5.6  ADR Reporting in Germany
5.6.1 The System
Pharmacovigilance in Germany is based on a highly complex and centralised system 
that was initiated in the 1970s . Regarding ADR reporting, there are two separate 
modus operandi, depending on whether the product under suspicion is synthetic or 
biological . Whereas ADRs related to synthetic medicines are centrally collected by 
the Federal Institute for Drugs and Medical Devices (Bundesinstitut für Arzneimit-
tel und Medizinprodukte, or BfArM), ADRs resulting from biologicals must be 
reported to the Federal Institute for Vaccines (Paul-Ehrlich-Institut, or PEI) . Even 
though both agencies are independent and act as centralised agencies, they have a 
nearly identical legal basis and have similar instruments at their disposal when it 
comes to pharmacovigilance and ADR reporting (Hagemann and Paeschke 2014) .
BfArM and PEI are both under the supervision of the Federal Ministry of Health 
(Hagemann and Paeschke 2014) . Both systems are presented in Fig . 5 .10 and 5 .11 
and are described in the following sections .
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Reporting
Healthcare professionals are not legally obligated to report ADRs, neither for 
synthetic nor biological medicines . They are merely bound by their professional 
codes of conduct (Ärztliche Berufsordnung, Article 6) . Accordingly, there are no 
sanctions for non-reporting .
Reporting by healthcare professionals . While physicians must report ADRs to 
the Drug Commission of the German Medical Association (Arzneikommission 
der deutschen Ärzteschaft, or AkdÄ), pharmacists are expected to submit their 
reports to the largest national association of pharmacists, the Drug Commission 
of German Pharmacists (Arzneikommission der Deutschen Apotheker, or AMK) . To 
facilitate data collection, reports can be submitted online, via regular mail or fax . 
Physicians and pharmacists receive confirmations of receipt for every submitted 
report, complemented with additional information and literature regarding the 
respective ADR . In urgent cases, reporters might be requested to provide further 
information, such as hospital reports . Sometimes, reporters are contacted via phone 
for further consultation or follow-up questions in case of lack of clarity .
The physicians’ and pharmacists’ associations in turn collect, evaluate and 
– excluding information regarding reporters – forward the reports they receive 
to BfArM, PEI and marketing authorisation holders . The collaboration between 
BfArM and the associations is regulated by an agreement created in 1995 . Since 
2011, there is an additional agreement governing the collaboration with the PEI . 
Collaboration includes the electronic exchange of ADR reports and reciprocal 
information exchange regarding newly discovered drug risks . Additionally, the 
Medical Committee on Drug Safety (Ärzteausschuss Arzneimittelsicherheit, 
or ÄAAS) was initiated at BfArM and PEI, which consists of AkdÄ experts (AkdÄ 
Tätigkeitsbericht 2015) .
Alternatively, healthcare professionals can voluntarily submit reports directly to 
the respective marketing authorisation holders or the national competent authority 
BfArM . Submitted reports are disseminated between the different actors so that 
double reporting is not necessary . In the end, all reports are centrally collected 
and saved in pseudonomised form by the BfArM, which forwards their reports to 
the respective marketing authorisation holder and to EMA as well as the WHO .
ADR reporting concerning biologicals works rather similarly . However, instead 
of reporting to the BfArM, AkdÄ and AKM need to forward the physicians’ and 
pharmacists’ reports to the Paul Ehrlich Institute for Vaccines .
However, there is one important difference when it comes to tissues, tissue-en-
gineered products and vaccines . In the case of ADRs related to these products, 
healthcare professionals do not submit the reports to their respective associations 
but to the state health authorities (Gesundheitsämter der Länder), which carry out 
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a first examination . Subsequently, these health authorities forward the reports to 
the PEI for central collection .
Reporting by marketing authorisation holders . In contrast to healthcare profes-
sionals, marketing authorisation holders are legally obligated to report every case 
they are informed about to the BfArM or, as regards biologicals, to the PEI (German 
Drug Law, Chapter 17) . In the case of non-compliance, sanctions can be imposed .
Patient Reporting . Patients have various options to report since the transposition 
of Directive 2010/84/EU in 2012 . They can submit reports directly to the national 
competent authorities, namely the BfArM or the PEI, via phone, e-mail or an online 
form . Additionally, they can call the respective marketing authorisation holder in 
order to report an unexpected side effect, or they can consult their physician or 
pharmacist .
Evaluation and Signal Detection
The evaluation of ADR reports takes place within the AkdÄ and AKM phar-
macovigilance units . After the reports’ completeness is verified, the reports are 
scientifically assessed regarding severity, causality and the necessity of further 
risk-minimising measures, including consultation of a database, medical advisers 
and research assistants . Evaluation and signal detection is carried out by a software 
program called ARTEMIS (Adverse Drug Reactions Electronic Management and 
Information System), which is used to look for similar cases in the shared BfArM 
and AkdÄ database . In cases of particularly severe ADRs or ambiguous causality 
assessments, additional scientific statements from experts are collected . Based on 
these evaluation procedures, selected cases are debated in the respective phar-
macovigilance units in order to decide on further procedures . In these settings, 
relevant public safety issues and necessary measures for risk minimisation – such 
as additional information for physicians and pharmacists or an alteration of mar-
ket authorisation – are debated . Relevant safety issues are communicated via the 
Deutsches Ärzteblatt, a weekly magazine, or via drug safety mails (Bronder and 
Stammschulte 2013) .
5.6.2 Perceived Challenges
Even though all respondents considered ADR reporting to work rather efficiently 
in Germany, several of them emphasized that there are still instances of underre-
porting, especially by healthcare professionals . As per the interviewees, this can 
predominantly be attributed to a general lack of awareness and sensitivity regarding 
ADR reporting as well as insufficient time and personnel .
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Lack of Awareness
According to our respondents, the healthcare professionals’ lack of awareness 
regarding ADR reporting can be traced back to various shortcomings in the ac-
ademic education of the relevant actors . Pharmacovigilance is only included in 
the curriculum of pharmacy studies, while other medical curricula do not impart 
any knowledge on drug safety in general and on pharmacovigilance in particular .
Recommendation: Awareness Raising – Healthcare Professionals
In order to tackle underreporting by healthcare providers, national authorities 
and healthcare institutions should invest in awareness-raising campaigns to 
increase professional knowledge about pharmacovigilance and sensitise relevant 
actors about its particular importance to ensure public health .
To improve both the quantity and quality of ADR reports, university classes 
about the importance of pharmacovigilance and ADR reporting should be 
mandatory for every medical and pharmacy student .
In addition, European, national or regional authorities should organise 
advanced post-graduate training on a regular basis to ensure that healthcare 
professionals acquire the necessary skills to cope with the complex task of ADR 
reporting .
It was further indicated that patients are not sufficiently aware that they are able 
to report and do not know how to do so . This suggests that the quantity of ADR 
reports could be increased if patients were better informed . Additionally, respon-
dents pointed out that reporting mechanisms for patients were still rather complex .
In addition, the quality of submitted ADR reports has been criticized by several 
interview partners . More precisely, it was pointed out that reports submitted via 
the national competent authority’s online forms are frequently incomplete . This 
leads to severe problems for data evaluation and signal detection . Incomplete 
reports cannot be processed adequately and are therefore invalid . Accordingly, 
missing information needs to be gathered in a follow-up process and this means a 
considerable increase in workload for the relevant actors .
In line with this, our respondents generally suggested that direct patient reporting 
was rather unconstructive . Instead, they agreed that patients who suspect an ADR 
should consult their physician first and file their reports in collaboration with them .
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Recommendation: Awareness Raising – Patients
In order to tackle underreporting by patients, European, national and regional 
authorities should invest in awareness-raising campaigns to increase the public 
knowledge about pharmacovigilance .
Authorities should raise awareness in the short term through various means 
of communication (e .g . websites, social media, leaflets) as well as in the long term 
through cooperation with schools to educate future generations .
In order to facilitate ADR reporting by patients, Member States should offer 
a wide range of possible communication channels, including web-based and pa-
per-based formats . Both web-based and paper-based formats should be designed 
to be as user-friendly as possible . For web-based formats, IT solutions should be 
developed to guide patients through the format and to ensure the completeness 
of reports . All formats should be accompanied by accessible manuals written 
in layman’s terms .
A first step in this direction is indicated by ongoing discussions about introducing 
a smartphone app intending to render ADR reporting more accessible to the public 
and thereby reduce reporting hurdles for patients . We consider this a good approach 
which should be pursued further .
Lack of Interconnectivity
Moreover, some respondents pointed out that the IT infrastructure of hospitals, 
pharmacies, associations and institutes is by no means connected . In some cases, 
there is still the need to manually transfer data from one system to another . This 
is a very time-consuming, complex and resource-intensive process, which is prone 
to mistakes and transcription errors .
A closely related problem is the duplication of ADR reports that occurs when 
identical reports are submitted by different actors, e .g . when patients report ADRs 
directly to the national competent authority and subsequently consult healthcare 
professionals, who then report the incident to the national competent authority 
a second time . Due to the particularly restrictive data protection laws in Germa-
ny, it is practically impossible to identify these duplications . In addition, unique 
characteristics are omitted from the reports at a very early stage of the process . 
Even though this ensures proper data protection, at the same time the detection 
of duplications is rendered impossible .
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Recommendation: Harmonisation of IT Systems
In order to cope with information overload and to facilitate the process of submit-
ting ADR reports, national and regional competent authorities should improve 
interconnectivity of IT systems, as for instance those of general practitioners, 
hospitals, pharmacies and the ADR reporting system .
In addition, the process of “who reports to whom” could be further facilitated 
and clarified, allowing for a more streamlined process and less data duplication .
Budgetary Constraints
Several interviewees described challenges regarding financial resources . Both 
national competent authorities, i .e . BfArM and PEI, are financially dependent 
on the Federal Ministry of Health . Accordingly, there is no room for quick and 
independent decision-making, resulting in delayed and insufficient reactions to 
changing demands .
Recommendation: Sufficient Financial Means for Relevant Actors
National and regional competent authorities working under the auspices of 
national ministries should be endowed with sufficient financial means to fulfil 
their functions . Likewise, healthcare institutions should be endowed with suffi-
cient means . Sound finances enable healthcare institutions to rely on a stronger 
workforce which reduces the workload of individual healthcare professionals 
and increases the possibility of extended reporting of ADRs .
Incomplete Reports
Finally, our respondents are largely satisfied with the functioning of ADR reporting 
and the identification and traceability of biologicals . The only caveat identified is 
that the product name and batch number cannot be reported in all cases . Inter alia, 
this can be attributed to rather vague legal requirements . However, the currently 
discussed Fourth Amendment to the German Drug Law (4. Gesetz zur Änderung 
arzneimittelrechtlicher und anderer Vorschriften) requires that both the brand name 
and batch number must be reported for ADRs relating to biologicals, which is a 
step in the right direction .
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5.6.3 Perceived Best Practices
The German pharmacovigilance system is deeply entrenched and well-appointed 
with manifold experts in the field . Because the pharmacovigilance system has been 
in place for more than 40 years, experience and routine both contribute to effective 
ADR reporting . Moreover, identification and traceability of biological medicines 
works particularly well because there is a separate system for biologicals .
Even though the German pharmacovigilance system is centralised, the national 
competent authorities are usually not directly contacted by healthcare profession-
als . Instead the physicians’ and pharmacists’ associations collect the reports and 
subsequently forward them . Hence, these associations act as points of contact be-
tween reporters and the authorities, thereby assuming a mediating role and allow 
for better communication between the relevant actors .
Awareness Raising
The national competent authorities provide several possibilities for engagement 
and educational activities for actors in the pharmacovigilance system . Healthcare 
professionals, patients and pharmaceutical companies can contact the authorities 
at any time in order to receive additional information on certain products or ADR 
reporting .
Additionally, Germany established several systems for spreading new information 
on risks of medicinal products to healthcare professionals . The so-called red-hand 
letter (Rote-Hand-Brief) is distributed via regular mail . The red hand printed on 
the cover signals that the letter does not contain an advertisement but important 
information related to pharmacovigilance (for further information see cf . Box 5 .6) .
Further, since December 2016, the so-called blue-hand letter (Blaue-Hand-Brief) 
has been introduced . Blue-hand letters contain additional and relevant educational 
information and material on specific medicines (cf . Box 5 .6)
Additionally, the AMK established, together with the Confederation of the 
Pharmaceutical Wholesale Trade (PHAGRO), an efficient fax information system 
aiming to inform pharmacists and other healthcare professionals about urgent 
risks (cf . Box 5 .7) .
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Cooperation
Pharmacovigilance educational and research centres are important for improving 
ADR reporting . A particularly good example in Germany is the Institute for Clin-
ical Teratology and Drug Risk Assessment in the Pregnancy and Nursing Period 
(Pharmakovigilanzzentrum Embryonaltoxikologie, or Embryotox), which is located 
in the Charité hospital in Berlin . This institute serves as a consultancy centre for 
healthcare professionals working in hospitals and advises the national competent 
authorities whenever problems or questions referring to ADRs in pregnancy and 
nursing periods arise . It also maintains an online database which is accessible to 
everyone .6 Moreover, it can forward ADRs to the national competent authorities .
Another advisory body in the German pharmacovigilance system is the Medical 
Committee on Drug Safety (ÄAAS), which also advises the national competent 
authorities with expertise on specific risks of medicinal products .
Box 5.6 Red- and blue-hand letters
In 1969, the German Pharmaceutical Industry Association introduced the red hand 
as a symbol to indicate the importance of the information provided in the letter . 
These letters with the red hand are distributed to all healthcare professionals . The 
unique red hand logo signals that the letter does not contain an advertisement 
but important information on newly detected risks of medicines or a defective 
batch . The red-hand letters are distributed in consultation with BfArM and PEI 
and are a common way to communicate medicinal risks in Germany .
The newly introduced blue-hand letter (in December 2016) contains educa-
tional material that has been approved by BfArM and PEI . More precisely, the 
letters provide additional information complementing the package leaflets and 
the summary of product characteristics and are directed to physicians, pharma-
cists or patients in order to alert them about certain risks . It is expected that the 
blue-hand letters will contribute towards improving the safe and correct use of 
medicinal products .
6 www .embryotox .de .
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Box 5.7 AMK/PHAGRO Schnellinformationssystem
Moreover, the AMK, in collaboration with the association of pharmaceutical 
wholesaler trading companies (PHAGRO), distributes information to pharma-
cies via a fax information system (AMK/PHAGRO Schnellinformationssystem) . 
This system was established in 1996 aiming at providing important and urgent 
information on drug safety risks on short notice . In the case of an emergency, 
the AMK, in close cooperation with the marketing authorization holder and the 
responsible national competent authority, drafts an informational notice, which 
includes the medicine’s name, the batch number and a description of the potential 
dangers . Moreover, recommended actions are enclosed . The informational notice 
is distributed via fax to every wholesale trader in Germany; these traders print 
them and enclose them with the invoices and delivery notes accompanying every 
single shipment to pharmacies . Because pharmacies are usually supplied every 
day, the informational notices reach end consumers very quickly .
An additional e-mail and fax system sends the information notices to the 
AkdÄ, hospital pharmacies, the German army medical service, public institutes, 
and diverse competent authorities at the state and federal levels . In addition, the 
informational notice is published, often including additional information, in the 
next AMK newsletter .
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